key: cord-0758250-stxk6rjx
authors: Maguire, Deirdre; McLaren, David S.; Rasool, Irum; Shah, Preet M.; Lynch, Julie; Murray, Robert D.
title: ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises
date: 2021-08-06
journal: Clin Endocrinol (Oxf)
DOI: 10.1111/cen.14566
sha: f36022b5ca23f5b7d23ade0e8a14d45b2e0241ba
doc_id: 758250
cord_uid: stxk6rjx

BACKGROUND: Patients with adrenal insufficiency (AI) have excess mortality, in part due to the occurrence of life‐threatening adrenal crises. Infective processes, including that of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), are recognised as the major precipitant of adrenal crises. Adverse reactions to the ChAdOx1 SARS‐CoV‐2 vaccine occur in a significant proportion of individuals, however, are mild‐moderate in the majority of cases. DESIGN: Case series. PATIENTS & RESULTS: We describe five cases where more severe adverse reactions to the ChAdOx1 SARS‐CoV‐2 vaccine led to actual or incipient adrenal crises requiring parenteral hydrocortisone within 24 h of receiving the first ChAdOx1 SARS‐CoV‐2 vaccination. CONCLUSION: In individuals with adrenal insufficiency, adverse reactions to the initial dose of the ChAdOx1 SARS‐CoV‐2 vaccination can precipitate adrenal crises. We recommend that patients with AI should immediately increase their maintenance glucocorticoid dosage 2–3 fold on experiencing any symptoms in the initial 24 h following vaccination.

Patients with adrenal insufficiency (AI) are considered at increased risk of infections and have a longer duration of recovery. 5 Infections are also the most frequent precipitant of lifethreatening adrenal crises (ACs). 6, 7 In the United Kingdom, therefore, AI has therefore been considered as an indication for early vaccination. At the onset of significant infections patients with AI are taught to increase their maintenance steroid dosage, generally 2-3 fold. This advice is not usually suggested for patients with AI when undergoing vaccinations. We describe five cases of adrenal crises (requiring parenteral glucocorticoids and intravenous fluids) 8 or incipient crises (requiring parenteral glucocorticoids) resulting from the first dose of the ChAdOx1 SARS-CoV-2 vaccination. All patients provided consent for the publication of the data. Adverse reactions tended to be mild to moderate in severity, resolved within a few days of vaccination, and are less frequent and severe with the second dose. 1, 4 Patients with both primary and secondary AI have been shown to have increased mortality and morbidity 9,10 contributed to, in part, by the occurrence of adrenal crises. The incidence of ACs has been reported to be 5.2-17 per 100 patient-years in PAI and 3.6-5.8 per 100 patientyears in SAI. 6, 7, 11, 12 Adrenal crises have been estimated to be fatal in around 6% of cases. 7 Infectious diseases, particularly gastroenteritis, are reported to be the most common precipitating factors for ACs. 6, 7, 11 Individuals with AI have higher rates of infections leading to more frequent hospital admissions. 5 Emotional stress, missed glucocorticoid doses or inadequate glucocorticoid dose escalation for intercurrent illness may also be factors facilitating ACs. 7, 13 Similar to other infective processes, our case series suggests the acute onset of often quite marked adverse reactions following the ChAdOx1 SARS-CoV-2 vaccine, including high fever and associated stresses are able to precipitate adrenal crises. In fact, the symptoms described by our cohort mirror those experienced by subjects in the initial efficacy studies of the ChA-dOx1 SARS-CoV-2 vaccine. None of our patients pre-empted the possibility that the vaccination could lead to a potential adrenal crisis, and therefore did not increase their maintenance HC dosage beforehand. The management of AI in the patients in this series were reflective of UK practice. 14, 15 All the individuals were on appropriate HC replacement regimens, had undergone regular education as to 'sick day' rules for managing their HC during intercurrent illness and stresses, had IM HC for emergency usage, and had been taught how to administer this.

The patients in this series came to attention over a period of four months; two during presentation at the emergency department, whereas the additional three patients contacted the endocrine specialist nurse following the event. Unfortunately, this series does not allow us to determine the incidence of occurrence of actual or incipient adrenal crises following ChAdOx1 SARS-CoV-2 vaccination within our cohort of patients with AI (n = ∼500) as the number vaccinated, vaccine type utilised, and whether further cases have occurred but presented to local hospitals is not currently known. Furthermore, although all subjects had received the ChAdOx1 SARS-CoV-2 vaccine in this series, this likely reflects the distribution of the vaccine and its usage within the United Kingdom. We are therefore unable to determine if alternate vaccines might similarly result in adrenal crises. In line with recommendations from the Addison's Disease Self Help Group (ADSHG), we strongly recommend that individuals with known AI immediately increase their maintenance glucocorticoid dosage 2-3 fold for 24 h should they experience any symptoms after receiving their COVID-19 vaccination. 16 It is also imperative that patients check they have HC for injection, that this is in date and are they or a close relative are confident in its usage before undergoing vaccination.

The cases series was proposed by DM and RDM which was then discussed between all authors. DSM, IR, PMS and JL brought together the clinical summaries and consented the patients. The initial manuscript was written by RDM. All authors reviewed and contributed to finalising the manuscript. 

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

http://orcid.org/0000-0001-6730-6109

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca

Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: a cohort study

Incidence of adrenal crisis in patients with adrenal insufficiency

High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study

European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy

Premature mortality in patients with Addison's disease: a populationbased study

Mortality in patients with pituitary disease

Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies

Characterization of patients with adrenal insufficiency and frequent adrenal crises

Daily adjustment of glucocorticoids by patients with adrenal insufficiency

Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity-data from the EU-AIR

Glucocorticoid management of adrenal insufficiency in the United Kingdom: assessment using real-world data

Bristol: Addison's Disease Self-Help Group